[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  J Keynes [@JKeynesAlpha](/creator/twitter/JKeynesAlpha) on x 8683 followers Created: 2025-07-17 20:00:07 UTC $NTLA Still holding strong: Intellia remains a future 10x in my view for anyone patient enough to wait. My bags are full and if it dips, I’ll buy more. The idea that Cas9 is obsolete because of prime editing? Nonsense. Cas9-based therapies like Casgevy are already approved and saving lives, with many more set to hit the market over the next 12–24 months. Own Intellia. Own $PRME too! XXXXX engagements  **Related Topics** [$ntla2002](/topic/$ntla2002) [$prme](/topic/$prme) [saving](/topic/saving) [approved](/topic/approved) [10x](/topic/10x) [$ntla](/topic/$ntla) [Post Link](https://x.com/JKeynesAlpha/status/1945936572387397795)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
J Keynes @JKeynesAlpha on x 8683 followers
Created: 2025-07-17 20:00:07 UTC
$NTLA Still holding strong: Intellia remains a future 10x in my view for anyone patient enough to wait. My bags are full and if it dips, I’ll buy more. The idea that Cas9 is obsolete because of prime editing? Nonsense. Cas9-based therapies like Casgevy are already approved and saving lives, with many more set to hit the market over the next 12–24 months. Own Intellia. Own $PRME too!
XXXXX engagements
